Samsung Biologics Co. will buy Switzerland-based PolyPeptide Group AG for cash, with the purchase price set at roughly 1.46 billion Swiss francs ($1.8 billion), representing the equity value of the contract drug manufacturer, a move that broadens its production capacity.
According to an official statement, the South Korean firm is paying 44.31 Swiss francs per share to acquire PolyPeptide. A company spokesperson said, "the per-share price represents a 6.1% premium over Friday's closing price and a 40% increase compared to the value before any acquisition speculation emerged."
PolyPeptide operates plants across Sweden, Belgium, France, the United States, and India, with capabilities spanning R&D, process development, and large-scale manufacturing.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
The acquisition reflects increasing demand from pharmaceutical companies for peptide-based treatments, particularly in the obesity and metabolic disease areas. By incorporating PolyPeptide's peptide production skills, Samsung Biologics is expected to bolster its position in the contract development and manufacturing sector, especially as drugmakers ramp up their need for such therapies.
Peptide drugs have become a major growth driver in the pharmaceutical industry, largely due to the success of GLP-1 receptor agonists used for diabetes and weight loss. Contract development and manufacturing organizations (CDMOs) that specialize in peptide synthesis are seeing rising demand as drug developers turn to outsourcing for complex production steps. Samsung Biologics, already a leader in large-molecule biologics, intends to combine PolyPeptide's established peptide capabilities with its own biologics platform to offer a full-service solution.
This deal aligns with broader industry trends where large CDMOs are acquiring specialized peptide manufacturers to meet surging demand. Competitors such as Thermo Fisher Scientific and Lonza have also expanded their peptide capabilities through acquisitions. Samsung Biologics, which operates large-scale bioreactor facilities in South Korea, aims to leverage PolyPeptide's global footprint to provide end-to-end services for both biologic and peptide-based therapies.
This strategic expansion positions the company to capture a larger share of the fast-growing peptide CDMO market, which industry analysts project will see double-digit growth through the end of the decade. The premium paid - 40% above pre-rumor levels - further signals the value Samsung Biologics places on entering this high-demand segment.
This acquisition allows the company to enter the rapidly expanding peptide drug segment, where treatments for chronic conditions like obesity and metabolic diseases are driving substantial outsourcing demand. The combined capabilities aim to offer clients a more comprehensive suite of services spanning both biologic and peptide drug development and manufacturing.
The surge in demand for GLP-1 agonists such as Ozempic and Wegovy has reshaped the CDMO landscape, with drugmakers racing to secure reliable peptide supply chains. Samsung Biologics' move into this space leverages its existing large-scale biologics infrastructure while adding PolyPeptide's specialized synthesis know-how, positioning it as a one-stop partner for complex therapeutic modalities.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
